Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not ...
News-Medical.Net on MSN
Smartphones match traditional methods in monitoring patients with muscular dystrophy
Stanford Medicine researchers found that a smartphone could monitor patients with two types of muscular dystrophy as well as ...
Investor's Business Daily on MSN
Sarepta Crashes After Two Muscular Dystrophy Drugs Fail Confirmatory Tests
Sarepta stock crashed late Monday after the biotech company said two of its muscular dystrophy drugs failed their ...
Because researchers have made such striking progress in developing drugs to treat neuromuscular diseases, Scott Delp, Ph.D., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback